Gain Therapeutics
$ 8.99 · 5 (761) · In stock
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.
Computational Drug Discovery With Gain Therapeutics Matthias Alder
Gain Therapeutics: Focused on developing new medicines for protein
Minoryx Therapeutics spins off SEE-Tx platform into new company
Broad Application of Gain Therapeutics' Structurally Targeted
Gain Therapeutics on LinkedIn: #jpm2024
Gain Therapeutics: Focused on developing new medicines for protein
How does Gain Therapeutics Platform quantify druggability of
Broad Application of Gain Therapeutics' Structurally Targeted
The Future Is Now: Matthias Alder Of Gain Therapeutics On How
Eric Richman Gain Therapeutics presents at the Jefferies
Gain Therapeutics First Quarter 2023 Earnings: Revenues Beat